P077. Neoadjuvant chemotherapy for stage II and III breast cancer increases breast conservation in all intrinsic breast cancer subtypes

      Background: Neoadjuvant chemotherapy (NAC) is increasingly being used to treat early breast cancer. One of the main benefits to the surgeon is the potential to down-size the tumour, thus facilitating breast-conserving surgery (BCS). Although the practice of BCS following NAC is now widely established, there is relatively little data on the impact of intrinsic breast cancer subtype on BCS conversion rates. The aim of this study was to evaluate differences in BCS rates between intrinsic breast cancer subtypes in patients undergoing NAC, in addition to clinical outcome.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect